MAIA Soars 20% on Interim Results From Lung Cancer Study
https://www.zacks.com/stock/news/2212386/maia-soars-20-on-interim-results-from-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2212386
Jan 18, 2024 - MAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.
0
Is it a Good Idea to Invest in Intellia (NTLA) Stock Now?
https://www.zacks.com/stock/news/2212290/is-it-a-good-idea-to-invest-in-intellia-ntla-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2212290
Jan 18, 2024 - Here, we discuss some reasons why investing in Intellia (NTLA) stock now may turn out to be a more prudent move than ever.
0
Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO
https://www.zacks.com/stock/news/2211548/aclaris-acrs-stock-rises-on-appointment-of-new-interim-ceo?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2211548
Jan 17, 2024 - Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.
0
Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now
https://www.zacks.com/stock/news/2210923/reasons-to-add-blueprint-bpmc-stock-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2210923
Jan 16, 2024 - Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.
0
Beat the Market the Zacks Way: DaVita, Block, Home Depot in Focus
https://www.zacks.com/stock/news/2210009/beat-the-market-the-zacks-way-davita-block-home-depot-in-focus?cid=CS-ZC-FT-analyst_blog|investment_ideas-2210009
Jan 15, 2024 - Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
0
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
https://www.zacks.com/stock/news/2209718/emergent-ebs-gets-235-8m-dod-contract-for-anthrax-vaccine?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209718
Jan 12, 2024 - Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.
0
Ligand (LGND) Up 9% on FDA Nod for Molluscum Infection Gel
https://www.zacks.com/stock/news/2207168/ligand-lgnd-up-9-on-fda-nod-for-molluscum-infection-gel?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207168
Jan 08, 2024 - Following the FDA approval, Ligand's (LGND) Zelsuvmi is the first at-home treatment option available for molluscum contagiosum.
0
Sanofi (SNY) Terminates Pompe Disease Deal as FTC Objects
https://www.zacks.com/stock/news/2196713/sanofi-sny-terminates-pompe-disease-deal-as-ftc-objects?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196713
Dec 12, 2023 - Sanofi (SNY) decides to end the licensing deal with Maze Therapeutics for MZE001, a phase II ready oral tablet for Pompe disease, due to the FTC's decision to block the deal.
0
Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study
https://www.zacks.com/stock/news/2195640/merck-s-mrk-keytruda-lynparza-combo-fails-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195640
Dec 08, 2023 - After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.
0
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
https://www.zacks.com/stock/news/2194285/pfizer-pfe-arvinas-post-upbeat-data-from-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2194285
Dec 06, 2023 - Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients.
0
<Page 2